References
1. 1. Mindermann T, Wilson CB: Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 1994; 41:359-364.
2. Molitch ME: Pathologic hyperprolactin-emia. Endocrinol Metab Clin North Am 1992; 21:877-901.
3. Webster J, Piscitelli G, Polli A, et al: A comparison of cabergoline and bromocri-ptine in the treatment of hyperprolac-tinemic amenorrhea. Cabergoline Comp-arative Study Group. N Engl J Med 1994; 331:904-909
4. Schade R, Andersohn F, Suissa S, et al: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356:29-38
5. Zanettini R, Antonini A, Gatto G, et al: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356:39-46.
6. Pouratian N, Sheehan J, Jagannathan J, et al: Gamma knife radiosurgery for medic-ally and surgically refractory prolactino-mas. Neurosurgery 2006; 59:255-266.
7. Castinetti F, Nagai M, Morange I, et al: Long-term results of stereotactic radios-urgery in secreatory pituitary adenomas, J Clin Endocrinol Metab 94:3400-3407, 2009
8. Colao A, Ferone D, Marzullo P, et al: Systemic complications of acromegaly: epidemiology, pathogenesis, and manage-ment. Endocr Rev 2004; 25:102-152.
9. Katznelson L: Diagnosis and treatment of acromegaly. Growth Horm IGF Res 2005.
10. Fahlbusch R, Honegger J, Buchfelder M: Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21:669-692.
11. Nomikos P, Buchfelder M, Fahlbusch R: The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical “cure”. Eur J Endocrinol 2005; 152:379-387.
12. Erturk E, Tuncel E, Kiyici S, et al: Outcome of surgery for acromegaly Perfo-rmed by different surgeons. Importance of surgical experience, Pituitary 8:93-97, 2005.
13. Freda PU, Katznelson L, van der Lely AJ, et al: Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005.
14. van der Lely AJ, Hutson RK, Trainer PJ, et al: Long-term treatment of acromegaly with pegvisomant, a growth hormone rece-ptor antagonist. Lancet 2001; 358:1754-1759.
15. Jenkins PJ, Bates P, Carson MN, et al: Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growthfactor-I in patients with acromegaly, J Clin Endocrinol Metab 91:1239-1245,2006.
16. Pollock BE, Jacob JT, Brown PD, et al: Radiosurgery of growth hormonepro-ducing pituitary adenomas. Factors associated with biochemical remission, J Neurosurg 106:833-838, 2007.
17. Jagannathan J, Pouratian N, Laws ER Jr, et al: Gamma knife radiosurgery for acrome-galy: outcomes after failed transsphenoidal surgery, Neurosurgery 62:1262-1270, 2008.
18. Biller BM, Grossman AB, Stewart PM, et al: Treatment of adrenocorticotropin depe-ndent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008; 93:2454-2462.
19. De Tommasi C, Vance ML, Okonkwo DO, et al: Surgical management of adrenoco-rticotropic hormone-secreting macroad-enomas: outcome and challenges in patients with Cushing's disease or Nelson's syndr-ome. J Neurosurg 2005; 103:825- 830.
20. Patil CG, Prevedello DM, Lad SP, et al: Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 2008; 93:358-362.
21. Minniti G, Osti M, Jaffrain-Rea ML, et al: Long-term follow-up results of postoper-ative radiation therapy for Cushing’s disease, J Neurooncol 84:79-84, 2007.
22. Höybye C, Grenbäck E, Rähn T, et al: Adrenocorticotropic hormone producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosur-gery, Neurosurgery 49:284-292, 2001.
DOI: https://dx.doi.org/10.18535/jmscr/v5i1.13
